Lonza Group AG
LONN
Rang in aandelen
#447
Lonza Group AG, together with its subsidiaries, operates as a contract... Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.
Aandeelprijs
$766.95
Marktkapitalisatie
$53.57B
Verandering (1 dag)
1.35%
Verandering (1 jaar)
9.01%
Land
CH
Handel Lonza Group AG (LONN)
Categorie
Healthcare
Winst voor Lonza Group AG (LONN)
Winst in 2026 TTM: 0
Volgens de meest recente financiële verslagen van Lonza Group AG bedraagt de huidige winst van het bedrijf 0. In 2026 behaalde het bedrijf een winst van 0, gelijk aan de winst van 2026, die 0 bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Lonza Group AG van 2004 tot 2026
Winst aan het einde van elk jaar
| Jaar | Winst | Wijzigen |
|---|---|---|
| 2025 | $1.39B | 77.01% |
| 2024 | $783.78M | -16.56% |
| 2023 | $939.36M | -40.02% |
| 2022 | $1.57B | 87.88% |
| 2021 | $833.60M | -4.61% |
| 2020 | $873.87M | 18.24% |
| 2019 | $739.09M | -9.57% |
| 2018 | $817.28M | 49.73% |
| 2017 | $545.84M | 48.94% |
| 2016 | $366.48M | 7.42% |
| 2015 | $341.15M | 21.46% |
| 2014 | $280.87M | 138.68% |
| 2013 | $117.67M | -48.71% |
| 2012 | $229.45M | 23.16% |
| 2011 | $186.30M | -47.24% |
| 2010 | $353.12M | 96.17% |
| 2009 | $180.00M | -59.52% |
| 2008 | $444.71M | 39.23% |
| 2007 | $319.41M | 55.15% |
| 2006 | $205.88M | 36.16% |
| 2005 | $151.21M | -3.96% |
| 2004 | $157.45M | 0.00% |
Winst van vergelijkbare bedrijven of concurrenten
| Bedrijf | Winst | Winstverschil | Land |
|---|---|---|---|
| $5.27B | - |
US
|
|
| $-3.09B | - |
US
|
|
| $-4.02B | - |
AU
|
|
| $1.95B | - |
NL
|
|
| $3.01B | - |
BE
|
